FIELD: biotechnology.
SUBSTANCE: group of inventions including a lipid nanoparticle for the treatment of liver tumor diseases in a patient, a pharmaceutical composition for the treatment of a liver tumor disease in a patient, and the use of a pharmaceutical composition for the production of a drug for the treatment of a liver tumor disease in a patient are described.
EFFECT: invention expands the arsenal of agents for the treatment of tumor diseases of the liver in a patient.
7 cl, 3 dwg, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PRODUCING MOUSE MODEL FOR STUDYING DUCHENNE MUSCULAR DYSTROPHY AND VERSIONS OF ITS THERAPY | 2023 |
|
RU2815936C1 |
BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
COMPOSITIONS AND METHODS FOR INHIBITION OF PROTEOLYTIC PATH OF ARGININE/N-DEGRON | 2020 |
|
RU2787841C2 |
METHOD FOR GENOTYPING NEISSERIA GONORRHOEAE ISOLATES ON BIOLOGICAL MICROCHIP | 2023 |
|
RU2816767C1 |
DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
SYSTEM OF TARGETED SPLICING CHANGES IN MARK2 GENE | 2023 |
|
RU2810907C1 |
MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
METHOD OF IDENTIFICATION OF SINGLE-NUCLEOTIDE POLYMORPHISMS IN MULTICOPY GENOME LOCUS USING LOOP-POLYMERASE CHAIN REACTION METHOD WITH SUBSEQUENT HYBRIDIZATION ON BIOLOGICAL MICROCHIP | 2022 |
|
RU2809184C1 |
Authors
Dates
2023-07-17—Published
2022-09-01—Filed